Bionaturis has recently held the III Technical Executive Committee of the Consortium SNC_Integra, led by Laboratorios Rovi and taking part Bionaturis and other companies such as Canvax, GMV, VivaCell, Vivia Allosterics and Vivia Biotech. The project is funded by the Centre for Industrial Technological Development (CDTI, in Spanish), by the public-private cooperation program for R&D initiatives, FEDER-INNTERCONECTA.

comite snc

The goal of this project is obtaining, in a completely safe and efficient way, new drugs to treat pathologies related to the Central Nervous System. Its main aim is to improve the patients’ quality of life and reduce the required health care.

After the meeting, the attendees could visit FLYLIFE’s facilities.

Treatment for the Gaucher disease

As it is published on the market, the main task of Bionaturis in this consortium is to develop an oral FLYLIFE version of the human recombinant glucocerebrosidase as ERT (Enzyme Replacement Therapy) for Gaucher disease type I. The goal is to improve the patients’ life, who nowadays are receiving the enzyme by intravenous infusion.

With the FLYLIFE version of this human enzyme, Bionaturis pretends to have a superior formulation to be stable until its absorption in the intestine facilitating membrane crossing and targeting the organs where the enzyme is required -liver, spleen, bone marrow, and Central Nervous System. As it was announced in the latest annual report, Bionaturis has developed the production protocol of the own version of the enzyme, called Bentoglucerasa (BNT001), with a yield that guarantees its industrial production. Bionaturis has shown its ‘in vitro’ activity and started a preclinical research in cell and mice models.

If you want to know more details about SNC_Integra, please click here.